corporate_fare

Modern Biosciences Limited

Address: 2nd Floor, 3 Pancras Square

Sponsor Overview

assignment

Specializations

Respiratory Fibrosis

Modern Biosciences Limited focuses on clinical research in idiopathic pulmonary fibrosis, with interest in disease mechanisms that affect lung function and progressive scarring of the lungs.

Idiopathic pulmonary fibrosis
Forced vital capacity outcomes
Pulmonary function assessment

Its current trial activity is centered on evaluating treatment effects in people living with IPF, reflecting a therapeutic focus on respiratory disease.

Interstitial Lung Disease

The sponsor’s research interest extends to interstitial lung disease with emphasis on conditions marked by declining breathing capacity and progressive lung tissue damage.

Fibrotic lung disease
Progressive lung impairment
Respiratory symptom burden

This area aligns with clinical efforts aimed at understanding and addressing chronic fibrotic disorders of the lung.

Oral Therapeutics

Modern Biosciences Limited is engaged in research involving oral therapy for chronic pulmonary disease, with attention to treatment delivery in a long-term outpatient setting.

Oral administration
Chronic respiratory treatment
Patient-friendly dosing

The funded study reflects interest in therapies intended for sustained use in patients with ongoing lung fibrosis.

Clinical Respiratory Outcomes

The sponsor’s clinical research activity includes outcomes relevant to respiratory medicine, particularly measures of lung capacity and functional decline in fibrotic disease.

Lung function endpoints
Breathing capacity
Disease progression monitoring

These interests place emphasis on clinically meaningful changes in pulmonary performance for patients with IPF.

Trial Name	Country	Status
Phase 2 Randomized, Double-Blind, Placebo-Controlled Study on the Efficacy and Safety of MBS2320 in Idiopathic Pulmonary Fibrosis Patients	France Germany Greece Hungary Italy Spain	Not Recruiting